Institute of Crystallography - CNR

Dipyridamole for tracking amyloidogenic proteins aggregation and enhancing polyubiquitination

Dipyridamole is currently used as a medication that inhibits blood clot formation and it is also investigated in the context of neurodegenerative and other amyloid related diseases. Here, we propose this molecule as a new diagnostic tool to follow the aggregation properties of three different amyloidogenic proteins tested (insulin, amylin and amyloid ? peptide 1-40). Results show that dipyridamole is sensitive to early stage amyloid formation undetected by thioflavin T, giving a different response for the aggregation of the three different proteins. In addition, we show that dipyridamole is also able to enhance ubiquitin chain growth, paving the way to its potential application as therapeutic agent in neurodegenerative diseases.

Year
2022
Journal
Archives of biochemistry and biophysics (Print)
Impact factor
4.114
RESEARCH AREA
KEYWORDS
Authors
Laneri, Francesca; García-Viñuales, Sara; Lanza, Valeria; Licciardello, Nadia; Milardi, Danilo; Sortino, Salvatore; Grasso, Giuseppe